These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1623 related items for PubMed ID: 18548981

  • 1. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 2. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP, Taggart AJ.
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [Abstract] [Full Text] [Related]

  • 3. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH, Seo GY, Lee JS, Kim TH, Yoo DH.
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [Abstract] [Full Text] [Related]

  • 4. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 7. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F, Michaud K.
    Am J Med; 2004 Mar 01; 116(5):305-11. PubMed ID: 14984815
    [Abstract] [Full Text] [Related]

  • 8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul 01; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 9. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

  • 10. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb 16; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 11. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.
    J Rheumatol; 2007 Apr 16; 34(4):706-11. PubMed ID: 17309133
    [Abstract] [Full Text] [Related]

  • 12. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C.
    Acta Reumatol Port; 2007 Apr 16; 32(2):139-50. PubMed ID: 17572652
    [Abstract] [Full Text] [Related]

  • 13. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT, Helfgott S.
    J Rheumatol; 2003 Nov 16; 30(11):2315-8. PubMed ID: 14677170
    [Abstract] [Full Text] [Related]

  • 14. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 16; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 15. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 16; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 16. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group.
    Arthritis Rheum; 2003 Aug 16; 48(8):2122-7. PubMed ID: 12905464
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V, Mergler S, Pleyer U.
    Curr Eye Res; 2010 Aug 16; 35(8):751-6. PubMed ID: 20673052
    [Abstract] [Full Text] [Related]

  • 18. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan 16; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 19. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 16; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 20. Biologics in rheumatoid arthritis.
    Sharma PK, Hota D, Pandhi P.
    J Assoc Physicians India; 2004 Mar 16; 52():231-6. PubMed ID: 15636315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.